Recent advances in the systemic treatment of metastatic papillary renal cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Beck SD, Patel MI, Snyder ME et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol.11(1), 71–77 (2004).
   PubMed Web of Science ®Google Scholar
• Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol.27(5), 612–624 (2003).
   PubMed Web of Science ®Google Scholar
• Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol.23(12), 2763–2771 (2005).
   PubMed Web of Science ®Google Scholar
• Reuter VE. The pathology of renal epithelial neoplasms. Semin. Oncol.33(5), 534–543 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Ronnen EA, Kondagunta GV, Ishill N et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer107(11), 2617–2621 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol.20(9), 2376–2381 (2002).
   PubMed Web of Science ®Google Scholar
• Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol.32(6), 590–595 (2001).
   PubMed Web of Science ®Google Scholar
• Yang XJ, Tan MH, Kim HL et al. A molecular classification of papillary renal cell carcinoma. Cancer Res.65(13), 5628–5637 (2005).
   PubMed Web of Science ®Google Scholar
• Kosaka T, Mikami S, Miyajima A et al. Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients. Clin. Exp. Nephrol.12(3), 195–199 (2008).
   PubMedGoogle Scholar
• Schmidt L, Junker K, Nakaigawa N et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene18(14), 2343–2350 (1999).
   PubMed Web of Science ®Google Scholar
• Inoue K, Karashima T, Chikazawa M et al. Overexpression of c-MET proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth. Virchows Arch.433(6), 511–515 (1998).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Walther MW, Zbar B. The genetic basis of cancer of the kidney. J. Urol.170, 2163–2172 (2003).
   PubMed Web of Science ®Google Scholar
• Yao M, Yoshida M, Kishida T et al.VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst.94(20), 1569–1575 (2002).
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J. Clin. Oncol.22(24), 4991–5004 (2004).
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat. Cell Biol.2(7), 423–427(2000).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int.97(5), 1102–1108 (2006).
   PubMed Web of Science ®Google Scholar
• Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int.98(3), 661–667 (2006).
   PubMedGoogle Scholar
• Paradis V, Ben Lagha N, Zeimoura L et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch.436, 351–356 (2000).
   PubMed Web of Science ®Google Scholar
• Dirim A, Haberal AN, Goren MR et al. VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int. Urol. Nephrol.40(4), 861–868 (2008).
   PubMedGoogle Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med.353(2), 172–187 (2005).
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103(2), 211–225 (2000).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9(1), 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.Blood101(9), 3597–3605 (2003).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24(1), 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Foran JM, Fiedler W et al. An innovative Phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res.9(15), 5465–5476 (2003).
   PubMed Web of Science ®Google Scholar
• Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J. Clin. Oncol.25(Suppl. 18) (2007) (Abstract 5010).
   Google Scholar
• Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a Phase II study. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5112).
   Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther.4(4), 677–685 (2005).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(16), 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Stadler WM, Figlin RA, Ernstoff MS et al. On behalf of the ARCCS investigators. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J. Clin. Oncol.25(Suppl. 18) (2007) (Abstract 5036).
   Google Scholar
• Beck J, Bajetta E, Escudier B et al. A large open-label, non-comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer (Suppl. 7), 244 (2007) (Abstract 4506).
   PubMedGoogle Scholar
• Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol.26(1), 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol. Cell. Biol.22(20), 7004–7014 (2002).
   PubMed Web of Science ®Google Scholar
• Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol.16(6), 928–933 (2005).
   PubMed Web of Science ®Google Scholar
• Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J. Surg. Oncol.84(3), 166–172 (2003).
   PubMedGoogle Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol.16(4), 525–537 (2005).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Dutcher J, Desouza P, Figlin R et al. Effect of temsirolimus versus interferon-α on survival of patients with advanced renal cell carcinoma of different tumor histologies. ASCO Genitourin. Cancers Symp. (2008) (Abstract 384).
   Google Scholar
• Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer109(11), 2257–2267 (2007).
   PubMed Web of Science ®Google Scholar
• Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin. Cancer Res.6(4), 1518–1523 (2000).
   PubMed Web of Science ®Google Scholar
• Pan C, Hussey M, Lara PN et al. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group study 0317. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5051).
   Google Scholar
• Eder J, Heath E, Appleman L et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J. Clin. Oncol.25(Suppl.) (2007) (Abstract 3526).
   Google Scholar
• Srinivasan R, Choueiri TK, Vaishampayan U et al. A Phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5103).
   Google Scholar
• Rathmell KA, Amin C, Wallen E, Pruthi R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). ASCO Genitourinary Cancers Symposium. (2008) (Abstract 370).
   Google Scholar